Indications
- Chronic open-angle glaucoma,
- increased intraocular pressure,
- condition after laser trabeculoplasty.
$26.00
Active ingredient: | |
---|---|
Dosage form: |
Â
With caution, the drug should be used for thyrotoxicosis, myasthenia gravis, diabetes mellitus, Raynaud’s syndrome, pheochromocytoma, bronchial asthma, and chronic obstructive bronchitis.
of 1 ml of eye drops contains:
active substance:
betaxolol 5 mg (in the form of betaxolol hydrochloride),
excipients:
benzalkonium chloride;
hypromellose;
sodium chloride;
sodium hydroxide;
disodium edetate;
water for injection
>
1 ml of eye drops contains:
Active ingredient:
betaxolol 5 mg (as betaxolol hydrochloride),
excipients:
benzalkonium chloride;
hypromellose;
sodium chloride;
sodium hydroxide;
disodium edetate;
water for injection
Xonef is a cardioselective beta-1-adrenoblocker without internal sympathomimetic activity. It has a weak membrane-stabilizing activity. It has a hypotensive effect associated with a decrease in the minute volume of the heart and a decrease in sympathetic stimulation of peripheral vessels.
When used in therapeutic doses, it does not have a cardiodepressive effect, does not affect glucose metabolism, does not reduce the bronchodilating effect of beta-adrenomimetics, and does not cause a delay in sodium ions in the body. Valid for a long time.
When applied topically in the form of eye drops, it lowers increased intraocular pressure. The resorptive effect is insignificant.
There is no sufficient experience of using Xonef during pregnancy and lactation.
The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother exceeds the potential risk to the fetus or child.
Use in children
Contraindicated in children and adolescents under 18 years of age.
With caution, the drug should be used for thyrotoxicosis, myasthenia gravis, diabetes mellitus, Raynaud’s syndrome, pheochromocytoma, bronchial asthma, and chronic obstructive bronchitis.
From the side of the organ of vision: often-short-term discomfort in the eyes after instillation, lacrimation; in some cases-decreased sensitivity of the cornea, redness of the eyes, pinpoint keratitis, photophobia, anisocoria, photophobia, itching, a feeling of “dryness” of the eyes, allergic reactions.
Systemic side effects are rare:
From the central nervous system: dizziness, nausea, drowsiness, insomnia, headache, depression, increased symptoms of myasthenia gravis.
From the cardiovascular system: bradycardia, impaired cardiac conduction and heart failure.
From the respiratory system: dyspnoea, bronchospasm, bronchial asthma, respiratory failure.
Concomitant use of Xonef and beta-blockers for oral use increases the risk of side effects (both local and systemic) due to the additive effect (therefore, patients receiving this combination of drugs should be under medical supervision).
When using Xonef in combination with drugs that deplete catecholamine stores (such as reserpine), a decrease in blood pressure and bradycardia may occur.
With simultaneous use of muscle relaxants and hypoglycemic agents, their effect may increase.
When combined with sympathomimetics, their vasoconstrictor effect is enhanced.
Caution should be exercised when using Xonef together with psychotropic drugs due to the possible increase in their effect.
Instill 1 drop 2 times a day in the affected eye.
During the first month, therapy is carried out under the control of the level of intraocular pressure, in the future, the frequency of measurement of intraocular pressure is determined individually.
In the case of using betaxolol after previous treatment with another similar drug, the dosage regimen is set individually.
If an excessive amount of the drug gets into the eyes, rinse your eyes with warm water.
Symptoms: with an overdose of beta-1-blockers, there may be a decrease in blood pressure, bradycardia, acute heart failure.
Treatment: perform symptomatic therapy.
Prescribe the drug with caution to patients:
It should be borne in mind that beta-blockers can cause symptoms similar to those of myasthenia gravis (diplopia, ptosis, general weakness).
Before elective surgery, beta-blockers should be gradually discontinued 48 hours before general anesthesia, as they may reduce the sensitivity of the myocardium to sympathetic stimulation during general anesthesia.
Patients taking beta-blockers may have a history of atopy or anaphylactic reactions. In the event of repeated hypersensitivity reactions, such patients may not be sensitive to the usual doses of epinephrine (epinephrine) needed to stop anaphylaxis.
When instilled in the eyes, beta-blockers can be absorbed into the systemic circulation. In this case, the same side effects may occur as with systemic use. Cases of severe respiratory and cardiovascular disorders, including bronchospasm with fatal outcome in patients with bronchial asthma and death from heart failure, are described.
Xonef has minimal effect on blood pressure and heart rate. However, caution should be exercised when prescribing the drug to patients with grade I AV block and mild to moderate heart failure. Treatment with Xonef should be stopped immediately when the first symptoms of decompensation from the cardiovascular system appear.
Xonef contains the preservative benzalkonium chloride, which can precipitate on soft contact lenses and have a toxic effect on the eye tissue. Therefore, patients wearing contact lenses should remove them before applying the drops and put them back no earlier than 20 minutes after instillation.
Influence on the ability to drive motor vehicles and manage mechanisms
If visual clarity is temporarily reduced after the use of drops in patients, it is not recommended to drive vehicles or engage in activities that require increased attention and reaction until it is restored.
Eye drops
In a dark place, at a temperature not exceeding 30 °C (do not freeze)
2 years
Betaxolol
By prescription
eye drops
Reviews
There are no reviews yet